2/11 Late treatment study
et al., J. Infection, doi:10.1016/j.jinf.2021.02.011 (Peer Reviewed)
Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: results of a large multicenter study
Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: results of a large multicenter study
Lopinavir/ritonavir retrospective study also showing univariate results for HCQ, with significantly lower mortality.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Lora-Tamayo et al., 2/11/2021, retrospective, Spain, Europe, peer-reviewed, 10 authors.
risk of death, 50.5% lower, RR 0.50, p < 0.001, treatment 7192, control 1361, odds ratio converted to relative risk, univariate.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
